Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents

Drugs

Volumn 66, Issue 8, 2006, Pages 1151-1168

  McCormack, Paul L ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; DEXAMETHASONE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; BINDING AFFINITY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; OSTEOLYSIS; PHARYNGITIS; POWDER INHALER; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; SHORT FORM 36; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHRONIC DISEASE; HUMANS; PREGNADIENEDIOLS; QUALITY OF LIFE;

EID: 33745459272     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666080-00011     Document Type: Review

References (44)

1. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: update on selected topics 2002. J Allergy Clin Immunol 2002 Nov; 110 (5 Suppl.): 141-209
2. Global Initiative for Asthma: global strategy for asthma management and prevention [online]. Available from URL: http://www.ginasthma.com [Accessed 2006 May 5]
3. Gupta R, Jindal DP, Kumar G. Corticosteroids: the mainstay in asthma therapy. Bioorg Med Chem 2004; 12 (24): 6331-42
4. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61 (9): 1325-50
5. Schering Corporation. Asmanex® Twisthaler® 220 mcg (mometasone furoate inhalation powder); US prescribing information [online]. Available from URL: http://www.spfiles.com/piasmanex.pdf [Accessed 2006 May 5]
6. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002; 15 (1): 35-50
7. Fardon TC, Lee DKC, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004 Nov 1; 170 (9): 960-6
8. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung Drug Res 1998 Sep; 48 (9): 956-60
9. Zhang X, Moilanen E, Adcock IM, et al. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 2002 Aug 16; 71 (13): 1523-34
10. Holgate ST, Arshad H, Stryszak P, et al. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J Allergy Clin Immunol 2000 May; 105 (5): 906-11
11. Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001 Aug 15; 164 (4): 569-74
12. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476-82
13. Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000 Dec; 118 (6): 1538-46
14. Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005 Jul; 128 (1): 70-7
15. Daley-Yates PT, Derks MGM, Weeks AT, et al. Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects [abstract no. B35 plus poster G25]. 101st International Conference of the American Thoracic Society; 2005 May 20-25; San Diego (CA)
16. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112 (3 Suppl.): S1-40
17. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005 Jan; 94 (1): 15-21
18. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40: 1227-36
19. Affrime MB, Kosoglou T. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma [abstract no. 346]. J Allergy Clin Immunol 2001; 107 (2): S104
20. Affrime MB, Cayen M, Kosoglou T, et al. The pharmacokinetics of mometasone furoate administered by dry powder inhaler in patients with chronic liver disease [abstract no. P37]. Ann Allergy Asthma Immunol 2001; 86 (1): 103
21. Yang TT, Li S, Wyka B, et al. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001 Winter; 14 (4): 487-94
22. Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000; 22 (12): 1483-93
23. Derendorf H, Daley-Yates PT, Pierre LN, et al. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 2002 Apr; 42 (4): 383-7
24. Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006 Feb; 34 (2): 225-33
25. Sahasranaman S, Issar M, Toth G, et al. Characterization of degradation products of mometasone furoate. Pharmazie 2004 May; 59 (5): 367-73
26. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000 Apr; 84: 417-24
27. Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000 Sep; 106 (3): 485-92
28. Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000 Nov; 106 (5): 852-60
29. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001 Jan; 86: 36-43
30. D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005 Aug; 21 (8): 1281-9
31. Karpel JP, Busse WW, Noonan MJ, et al. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005 Dec; 39 (12): 1977-83
32. Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006 Apr; 96 (4): 533-40
33. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93: 603-12
34. Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler®. Eur Respir J 2000; 16 (5): 808-16
35. Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001 Feb; 86: 203-10
36. O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001 Apr; 86 (4): 397-404
37. Wardlaw A, Larivee P, Eller J, et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004 Jul; 93 (1): 49-55
38. Corren J, Berkowitz R, Murray JJ, et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003 Sep; 57 (7): 567-72
39. Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 2003 Jun; 40 (4): 383-93
40. Lockey F, Abreu P, Kimel M, et al. Health-related quality of life effects of mometasone furoate dry-powder inhaler in patients with mild to moderate persistent asthma previously using inhaled corticosteroids [abstract no. P1834]. Eur Respir J 2003; 22 Suppl. 45: 283s.
41. Plus poster presented at the 13th European Respiratory Society Annual Congress; 2003 Sep 27-Oct 1; Vienna
42. Gillissen A. Managing asthma in the real world. Int J Clin Pract 2004 Jun; 58 (6): 592-603
43. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100 (6): 771-4
44. Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med 1998; 158 (3): 1002-7